PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1419029
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1419029
Plasma Protein Therapeutic Market size was valued at USD 30,053 Million in 2023, expanding at a CAGR of 6.5% from 2024 to 2032.
Plasma protein therapies are exceptional biologic medications that are administered through infusion or injection to address a diverse range of uncommon, life-threatening, chronic, and genetic ailments. These conditions encompass bleeding disorders, immune deficiencies, pulmonary disorders, neurological disorders, shock and trauma, liver cirrhosis, as well as infectious diseases like tetanus, hepatitis, and rabies. The utilization of plasma-derived medicines is crucial for patients suffering from rare diseases that can solely be managed through these therapies. Moreover, these medicines play a vital role in everyday medical practices, emergency and critical care scenarios, and preventive medicine. On a daily basis, approximately 300,000 European patients heavily rely on plasma protein therapies to effectively treat various critical medical conditions. These conditions may include rare genetic diseases, chronic ailments, or life-threatening medical emergencies resulting from accidents and trauma. For these patients, plasma-derived medicines serve as a lifeline by aiding the body in replacing missing or deficient proteins. The absence of consistent access to these treatments would result in the loss of many lives or a significant decline in the quality of life for these individuals.
Increase in autoimmune disorders, immune deficiency disorders, neurological and bleeding disorders are projected to drive the growth of market.
Plasma protein therapeutics, such as plasma-derived immunoglobulins, are utilized in the treatment of specific autoimmune disorders. The rising prevalence of autoimmune diseases contributes to the increasing demand for plasma-based therapies, thereby propelling market expansion. Based on comprehensive research and data collected from countries with robust epidemiological resources, such as the Scandinavian countries, it is estimated that autoimmune diseases collectively affect approximately 3% of the US population, equivalent to around 10 million individuals. To better comprehend this estimation considers the current US population of 329 million. Additionally, the market is expected to witness a surge in the incidence of immune deficiency disorders, neurological disorders, and bleeding disorders, resulting in a larger patient pool necessitating therapeutic interventions. The prevalence of neurological disorders specifically can drive the demand for these therapeutic options. The prevalence rates of various neurological disorders across different regions of the country range from 967 to 4,070 per 100,000 population, with an average of 2,394, indicating that over 30 million people are affected by neurological disorders. Moreover, ongoing advancements in therapeutic technologies, such as the development of recombinant proteins and engineered plasma proteins, present opportunities for innovation within the market. However, it is important to note that the high cost of treatment and the potential risks of contamination and transmission may impede the growth of the market.
The Global Plasma Protein Therapeutic Market is segmented on the basis of Product Type, Application and Region.
The market is divided into three categories based on product type: Albumin, Immunoglobulin, Plasma-derived Factor VIII and Others. The market is largely influenced by the dominance of the Immunoglobulin segment. Immunoglobulin products hold significant importance in the Plasma Protein Therapeutic market as they are vital in treating a range of medical conditions such as immunodeficiency disorders, autoimmune diseases, and neurological disorders.
The market is divided into two categories based on application: Hemophilia, Primary Immunodeficiency Disorder (PIDD), Idiopathic Thrombocytopenic Purpura (ITP) and Others. The market is primarily dominated by the segment of Primary Immunodeficiency Disorder (PIDD). In cases of PIDD, where the immune system is compromised, patients frequently experience a deficiency in antibodies. Immunoglobulin Replacement Therapy, which is derived from human plasma, plays a crucial role in the management of PIDD. This therapy entails the administration of immunoglobulins to bolster the patient's immune response.
Geographically, this market is spread across various regions including North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided based on the countries involved in business activities. The growth of the market is expected to be dominated by the Asia Pacific region, primarily due to its well-established healthcare infrastructure and the focused efforts of market players in research and development for plasma protein therapeutics. In recent years, Asia Pacific has witnessed significant growth in its healthcare infrastructure, with investments being made in medical facilities, hospitals, and research centers, thereby contributing to the overall improvement of the healthcare ecosystem. Notably, the Chinese government has successfully established a robust healthcare system, which is quite challenging considering the country's status as the largest developing nation in the world. Through continuous efforts of successive governments, the Chinese mainland is projected to have a total of 1,030,935 healthcare institutions by the end of 2021, including 36,570 hospitals and 977,790 primary-level clinics. In terms of market size, Europe holds the second-largest position during the forecast period, driven by the increasing demand for advanced treatment options and the growth of developing economies.
In contrast to the conventional pharmaceutical industry, the plasma industry utilizes human blood plasma, a living cell, as its primary material for producing life-saving medications. The production of these medications relies on a limited supply of raw material, which is generally more expensive and complex to obtain compared to non-living molecules and biologics grown in biotechnology facilities. To remain competitive in the market, ongoing research and development efforts are crucial. Companies allocate investments towards the development of new and improved plasma-derived products, the enhancement of manufacturing processes, and the exploration of new therapeutic applications. Biotechnology advancements, such as the creation of recombinant proteins, are areas of focus for many companies as they strive to meet the increasing demand for safer and more sustainable treatment options. Companies with a global presence have an advantage in accessing diverse markets. They establish manufacturing facilities, distribution networks, and partnerships to ensure the availability of their products in various regions. As the demand for plasma-derived therapies continues to rise, companies are likely to persist in investing in research and development, exploring strategic partnerships, and adapting to evolving market dynamics to maintain their competitive edge.
In May 2023, Biotest AG now has 28 nations on its market due to marketing authorizations it was granted to sell Cytotect, a CMV-hyper immunoglobulin, in five more countries: the Czech Republic, Slovakia, Lituania, Ireland, and Romania.